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Abstract:  Methylone (2-methylamino-1-[3,4-methylenedioxyphenyl]propane-1-one) is a synthetic hallucinogenic   
amphetamine analog, like MDMA (3,4-methylenedioxy- methamphetamine), considered to act on monoaminergic   
systems. However, the psychopharmacological profile of its cytotoxicity as a consequence of monoaminergic deficits  
remains unclear. We examined here the effects of methylone on the transporters for dopamine (DAT), norepinephrine 
(NET), and serotonin (SERT), using a heterologous expression system in CHO cells, in association with its cytotoxicity. 
Methylone inhibited the activities of DAT, NET, and SERT, but not GABA transporter-1 (GAT1), in a concentration-
dependent fashion with a rank order of NET > DAT > SERT. Methylone was less effective at inhibiting DAT and  
NET, but more effective against SERT, than was methamphetamine. Methylone alone was not toxic to cells except at  
high concentrations, but in combination with methamphetamine had a synergistic effect in CHO cells expressing   
the monoamine transporters but not in control CHO cells or cells expressing GAT1. The ability of methylone to   
inhibit monoamine transporter function, probably by acting as a transportable substrate, underlies the synergistic effect  
of methylone and methamphetamine.  
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INTRODUCTION 
  Various illegal and/or restricted “designer drugs” have 
been created by modifying amphetamines. Methylone (2-
methylamino-1-[3,4-methylenedioxy- phenyl]propane-1-one) 
is one such synthetic hallucinogenic amphetamine analogue, 
which resembles MDMA (3,4-methylenedioxymetham- 
phetamine) but differs structurally by the presence of a   
ketone at the benzylic position [1, 2]. This compound has 
been newly placed under legal control as a drug of abuse in 
Japan [3].  
  Because of its structural similarity to MDMA, methylone 
is thought to act on monoaminergic systems. A behavioral 
study by Dal Cason et al. [4] found that methylone substi-
tuted for MDMA in rats trained to discriminate MDMA from 
saline. In studies of its pharmacology in vitro methylone was 
threefold less potent than MDMA at inhibiting platelet sero-
tonin transporter (SERT) and as potent as MDMA in inhibit-
ing transporters for dopamine (DAT) and norepinephrine 
(NET), but only weakly inhibited the vesicular monoamine 
transporter [5, 6]. However, there have been few pharmacol-
ogical investigations of methylone in animal models, or stud-
ies about its mechanism of action.  
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  In addition, the cytotoxicity of MDMA is considered a 
consequence of monoaminergic deficits through the drug’s 
effects on the plasmalemmmal and vesicular monoamine 
transporters [7, 8]. Again, methylone may resemble MDMA 
in cytotoxic profiles. However, Nakagawa et al. [9] reported 
that methylone did not exhibit cytotoxic effects on isolated 
rat hepatocytes in contrast to MDMA and its analogues. The 
possibility can not be excluded that methylone is cytotoxic in 
some circumstances, since Nagai et al. [6] observed that like 
MDMA, it reduced mitochondrial membrane potential.  
  Recently, we examined the effects of 5-methoxy-N, N-
diisopropyltryptamine (5-MeO-DIPT), known as Foxy, on 
monoamine neurotransmitter transporters, including DAT, 
NET and SERT, using a heterologous expression system in 
COS-7 cells and rat brain synaptosomes, in association with 
its cytotoxicity [10]. In the present study, we used the same 
strategy to evaluate the relationship between the effects of 
methylone and methamphetamine on monoamine transport-
ers and cell toxicity. 
  The results indicated an ability of methylone to inhibit 
monoamine transporter function, and cause damage syner-
gistcally with methamphetamine in cells heterologously   
expressing monoamine transporters, suggesting that the 
transport of these drugs underlies their cytotoxicity.  
MATERIALS AND METHODS 
Materials 
  Methylone was synthesized at the Division of Pharma-
cognosy, Phytochemistry and Narcotics, National Institute of Methylone and Monoamine Transporters  Current Neuropharmacology, 2011, Vol. 9, No. 1    59 
Health Sciences (Tokyo, Japan). Its structure and purity were 
confirmed by melting point (degradation, 225°C), TLC, GC-
MS and 
1H-NMR analyses [11]. Other chemicals used were 
purchased from commercial sources. [
3H]Dopamine (DA) 
(1.29 TBq/mmol), [
3H]serotonin (5-HT) (1.04 TBq/mmol), 
and [
3H]GABA (1.2 TBq/mmol) were obtained from Perki-
nElmer Life Science, Inc. (Boston, MA, USA), and [
3H] 
norepinephrine (NE) (1.18 TBq/mmol) from GE healthcare 
Bioscience, Inc. (Buckinghamshire, UK).  
Cell Culture and Expression 
  Chinese hamster ovary (CHO) cells were cultured at 
37°C under 5 % CO2  / 95 % air in Minimum Essential   
Medium-alpha (-MEM) supplemented with 10 % fetal calf 
serum, 100 units/ml penicillin G, 100 μg/ml streptomycin, 
and 0.25 μg/ml fungisone.  
  For the preparation of cell lines stably expressing trans-
porters, CHO cells at subconfluence were transfected with 
cDNA of rat DAT (rDAT), NET (rNET), or SERT (rSERT), 
or mouse GABA transporter-1 (mGAT1) using FuGENE6 
transfection reagent (Roche Diagnostics, Mannheim, Ger-
many) according to the manufacturer’s directions. The cells 
were then diluted sequentially, seeded in 96-well plates, and 
selected using G418. The cell lines were confirmed to stably 
express the transporters based on the uptake of each tritium-
labeled ligand, and designated CHO/rDAT, CHO/rNET, 
CHO/rSERT and CHO/mGAT1, respectively. 
Uptake and Release Assay 
  The uptake assay using radio-labeled ligands was per-
formed, as described previously [10, 12]. Cells were washed 
three times with an oxygenated Krebs Ringer HEPES-
buffered solution (KRH; 125 mM NaCl, 5.2 mM KCl, 1.2 
mM CaCl2, 1.4 mM MgSO4, 1.2 mM KH2PO4, 5 mM glu-
cose, and 20 mM HEPES, pH 7.3) and incubated for 10 min 
at 37°C with 10 nM of [
3H]DA or other radio-labeled ligand. 
Nonspecific uptake was determined in mock-transfected 
cells and also in each plate in the presence of 100 μM co-
caine for monoamine and 1 mM nipecotic acid for GABA. 
Data were analyzed using Eadie-Hofstee plots with Prism 5 
(GraphPad Software, Inc., San Diego, CA). Statistical analy-
ses were performed using the unpaired Student’s t-test.  
  Reverse transport (release) was analyzed, as described 
[10]. Cells loaded with [
3H]substrate were incubated with or 
without the drug under investigation at 37°C for 2 min, and 
separated from the incubation solution. The radioactivity 
retained in the cells and also in the separated solution was 
measured by liquid scintillation counting. Statistical tests 
were performed using an analysis of variance (Kruskal-
Wallis test) with pairwise comparisons using Dunn’s multi-
ple comparison test. 
Cell Toxicity Assay 
  The amount of lactate dehydrogenase (LDH) released 
into the culture medium was measured for the evaluation of 
methylone’s toxicity, as described previously [12] with some 
modifications. Briefly, cells cultured in 96-well culture 
plates were washed and incubated without phenol red in -
MEM supplemented with 1% BSA and different concentra-
tions of methylone and/or methamphetamine for 24 h. The 
amount of LDH released into the medium was measured 
colorimetrically (Wako, Tokyo, Japan). Statistical analyses 
were performed using the Kruskal-Wallis test and Dunn’s 
multiple comparison test. 
RESULTS 
Effects of Methylone on the Uptake of Substrate in CHO 
Cells Stably Expressing Monoamine and GABA Trans-
porters 
  The effect of methylone on the transport of monoamines 
was examined in CHO cells stably expressing the rat mono-
amine transporters, rDAT, rNET and rSERT, in comparison 
with that on the mouse GABA transporter, mGAT1. Simul-
taneous incubation with [
3H]DA, [
3H]NE, or [
3H]5HT and 
methylone caused a decrease in the uptake of [
3H]substrate 
in a concentration-dependent fashion, although the effects 
differed between transporters in contrast to the effects of 
methamphetamine (Fig. 1). The rank order of the transport-
ers in terms of the potency with which they were inhibited by 
methylone was NET > DAT >> SERT (Fig. 1 and Table 1). 
Methylone inhibited SERT more, DAT and NETless, than 
methamphetamine. However, it had no effect on GAT trans-
port activity at concentrations up to 1 mM (Fig. 1), while 
nipecotic acid, an inhibitor of neuronal GABA transporter 
such as GAT1, inhibited [
3H]GABA uptake in a concentra-
tion-dependent manner (data not shown).  
 
 
 
 
 
 
 
 
Fig. (1). Effects of methylone on the uptake of substrates in 
CHO cells stably expressing monoamine and GABA transport-
ers. Cells were incubated with [
3H]substrates at 10 nM in the ab-
sence or presence of methylone at various concentrations. Specific 
uptake was expressed as a percentage of the control, and values 
represent the mean ± SEM, n=3. Control uptake in the absence of 
drugs was 4715 ± 182, 4961 ± 170, 13964 ± 1135, and 798 ± 114 dpm/ 
well for DAT, NET, SERT and GAT, respectively. 
Table 1.  Effects of Methylone and Methamphetamine on the 
Uptake of Monoamines in CHO Cells Stably Ex-
pressing rat DAT, NET and SERT 
IC50 (μM) 
Transporter 
Methylone Methamphetamine 
DAT 2.84  ± 0.36  0.65 ± 0.06 
NET 0.48  ± 0.03  0.16 ± 0.00 
SERT 8.42  ± 1.01  27.62 ± 2.87 
Values represent the mean ± SEM for three experiments each performed in triplicate. 
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  Next, we analyzed the effect of methylone on uptake 
kinetically. Table 2 summarizes the effects on [
3H]substrates 
in comparison with those of methamphetamine. Methylone 
increased the Km value without changing the Vmax for the 
uptake of [
3H]NE, indicating competitive inhibition similar 
to metamphetamine (Table 2). On the other hand, it showed 
uncompetitive inhibition of [
3H]DA and [
3H]5-HT, tending 
to decrease the Vmax while increasing the Km, as metham-
phetamine did.  
Effects of Methylone and Methamphetamine on the   
Reverse Transport of [
3H]substrates  
  To further characterize the effects of methylone on the 
monoamine transporters, we examined its influence on the 
reverse transport of [
3H]substrates through DAT, NET and 
SERT in comparison with methamphetamine, since unlike 
cocaine, methamphetamine induces the release of mono-
amines via a reversal of transport [13]. Methylone elicited 
the release of [
3H]DA, [
3H]NE and [
3H]5-HT from the cells 
expressing rDAT, rNET and rSERT, respectively, similar to 
methamphetamine (Fig. 2). In addition, the combination of 
methylone and methamphetamine did not cause a further 
increase in the release of [
3H]substrates.  
Cytotoxicity Elicited by Methylone and/or Metham-
phetamine 
  Initially, we examined the effect of methylone and meth-
amphetamine on cell viability using a MTT-based WST-1 
assay previously applied to Foxy [10]. However, we found 
no changes with methylone and/or methamphetamine at any 
concentrations tested (data not shown). Therefore, we used a 
LDH release assay to evaluate methylone’s toxicity. 
Table 2.  Changes in the Transport Kinetics Induced by Methylone and Methamphetamine in CHO Cells Stably Expressing the 
Monoamine Transporters 
 K m (μM) Vmax (fmol/μg protein/min) 
DAT 
Control  1.73 ± 0.55  34.12 ± 7.64 
Methylone 5μM  2.33 ± 0.67  26.68 ± 8.70 
Methamphetamine 1μM  2.06 ± 0.83  24.18 ± 9.89 
NET 
Control  0.25 ± 0.03  3.63 ± 0.31 
Methylone 0.5μM  0.58 ± 0.10*  4.54 ± 1.01 
Methamphetamine 0.2μM  0.71 ± 0.20  4.69 ± 0.49 
SERT 
Control  0.27 ± 0.04  40.68 ± 7.23 
Methylone 10μM  1.12 ± 0.25*  36.95 ± 5.68 
Methamphetamine 30μM  0.86 ± 0.21*  31.41 ± 4.63 
Values represent the mean ± SEM for three experiments each performed in triplicate. *P<0.05 vs control. 
 
 
 
 
 
 
 
Fig. (2). Effects of methylone and methamphetamine on the reverse transport of [
3H]substrates through the monoamine transport-
ers. CHO cells stably expressing rDAT, rNET, or rSERT were preloaded with a [
3H]substrate at 20 nM for 30 min. They were then washed 
with KRH buffer, and incubated for 2min in fresh medium containing 100 μM methylone and/or 100 μM methamphetamine. Values repre-
sent the mean ± SEM, n=8-11, and are expressed as a percentage of the control (without drugs). *P< 0.05, **P< 0.01 vs control. 
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 Fig.  (3) shows the cytotoxicity of methylone and meth-
amphetamine in CHO cells stably expressing rDAT, rNET 
and rSERT, together with mGAT1 as a control. Methylone 
did not induce the release of LDH from any cell line except 
that expressing SERT (Fig. 3). Furthermore, in combination 
with methamphetamine it caused a significant increase in the 
release of LDH in the cells stably expressing the monoamine 
transporters but not in the control CHO cells or cells express-
ing GAT (Fig. 3). 
DISCUSSION 
  The present study demonstrated that methylone acts as a 
non-selective inhibitor of the monoamine neurotransmitter 
transporters DAT, NET and SERT, with a rank order in 
terms of potencies of NET > DAT >> SERT. Kinetic analy-
ses revealed the characteristics of the inhibition to resemble 
those by methamphetamine. In addition, methylone induced 
a reversal of transport similar to methamphetamine. Meth-
amphetamine, like amphetamine, is transported by DAT and 
NET, and probably SERT [13]. The present study demon-
strated that methylone had similar properties to metham-
phetamine not only in inhibiting the uptake by transporters 
but also in reversing the direction of transport, suggesting 
that it too is likely to be a transportable inhibitor. However, 
methylone itself was cytotoxic only at high concentrations, 
though in combination with methamphetamine it had a sig-
nificant effect on cells expressing the monoamine transport-
ers but not the control CHO cells or cells expressing GAT. 
These results suggest that the transport of methylone through 
monoamine transporters underlies the cytotoxicity.  
  The effectiveness of methylone and methamphetamine in 
inhibiting the uptake of substrates by monoamine transport-
ers demonstrated here was well consistent with previous 
findings [5, 6]. Cozzi et al. [5] found that methylone inhib-
ited DAT more than NET, while Nagai et al. [6] and our-
selves observed a more potent effect on NET than DAT. On 
the other hand, Nagai et al. [6] reported that methylone in-
hibited DAT and SERT equally, while Cozzi et al. [5] and 
ourselves found the effect to be weaker at SERT than DAT. 
The discrepancy may be due to the different preparations or 
concentrations of labeled substrates used.  
  The concentrations of methylone in the brain at dosages 
at which the drug is abused, 100 – 200 mg [14], are un-
known. Experiments with rats demonstrated the intraperito-
neal administration of methylone at 5 mg/kg to be followed 
by a rapid increase in the plasma concentration ranging from 
700 to 1500 ng/mL within 15 or 30 min [11]. These values 
seem compatible with those for MDMA [7]. Therefore, the 
present findings suggest that methylone may inhibit mono-
amine transporters in the CNS at concentrations relevant to 
its abuse.  
  The present study demonstrated cytotoxicity at high con-
centrations, as assessed from the amount of LDH released in 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Effect of methylone and methamphetamine on viability of CHO cells stably expressing monoamine and GABA transporters. 
Cells were seeded on 96-well culture plates and cultured for 24 h prior to treatment with the drug under examination. They were then incu-
bated with various concentrations of methylone and/or methamphetamine for 24h, after which the amount of LDH released into the medium 
was determined. Values are expressed as a percentage of the control (absence of drugs), and represent the mean ± SEM, n=6-16. **P<0.01, 
***P<0.001 vs control. 
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CHO cells. This effect was observed in cells expressing the 
monoamine transporters, especially those expressing SERT, 
but not cells expressing mGAT1, suggesting a relationship 
with the transport of methylone, although the affinity of the 
transporter for methylone does not explain the potency of 
methylone’s toxicity. In addition, the present study demon-
strated that methylone and methamphetamine combined had 
a supra-additive effect on the release of LDH in CHO cells 
expressing monoamine transporters. The cytosolic accumula-
tion of monoamines or methamphetamine may cause oxida-
tive stress, resulting in cell death [15]. Therefore, one may 
assume that methylone modulates the toxic effects of other 
monoaminergic agents, such as methamphetamine and 3,4-
methylenedioxymethamphetamine (MDMA), through inter-
action at monoamine transporters. Recently, Shimizu et al. 
[14] reported a case study of a 27-year-old male who took 
methylone and 5-MeO-MIPT after ingesting a drug powder 
called pure methylone obtained via the internet, suggesting 
that substance-related disorders may be complicated by the 
combined use of psychoactive drugs. According to recent 
analyses, “ecstacy” and other designer drugs consist of mix-
tures of MDMA and other substances [16, 17]. Therefore, it 
is important to note their cytotoxicity when taken simultane-
ously. Further study is needed to clarify this issue. 
  In summary, we investigated the effects of methylone on 
monoamine transporters. The ability of methylone to inhibit 
transporter function, and damage cells heterologously ex-
pressing monoamine transporters, suggests that the transport 
of methylone underlies its cytotoxicity. 
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